Zobrazeno 1 - 10
of 37
pro vyhledávání: '"Robert N Schuck"'
Autor:
Robert N Schuck, Weibin Zha, Matthew L Edin, Artiom Gruzdev, Kimberly C Vendrov, Tricia M Miller, Zhenghong Xu, Fred B Lih, Laura M DeGraff, Kenneth B Tomer, H Michael Jones, Liza Makowski, Leaf Huang, Samuel M Poloyac, Darryl C Zeldin, Craig R Lee
Publikováno v:
PLoS ONE, Vol 9, Iss 10, p e110162 (2014)
Fatty liver disease is an emerging public health problem without effective therapies, and chronic hepatic inflammation is a key pathologic mediator in its progression. Cytochrome P450 (CYP) epoxygenases metabolize arachidonic acid to biologically act
Externí odkaz:
https://doaj.org/article/29650032df5d48bc836fda83e9a5f696
Autor:
Lingshan Wang, Jie Wang, Ji Feng, Mary Doi, Salvatore Pepe, Michael Pacanowski, Robert N. Schuck
Publikováno v:
Orphanet Journal of Rare Diseases, Vol 17, Iss 1, Pp 1-8 (2022)
Abstract Background The small patient populations inherent to rare genetic diseases present many challenges to the traditional drug development paradigm. One major challenge is generating sufficient data in early phase studies to inform dose selectio
Externí odkaz:
https://doaj.org/article/b4c43e84434c4e4da686f28dd247da2c
Publikováno v:
Clinical and Translational Science, Vol 12, Iss 3, Pp 236-239 (2019)
Selecting a dose regimen that is both safe and effective for patients is one of the most critical elements of a successful drug development program. Titrating the dose regimen of a drug based on patient response may help to identify safe and effectiv
Externí odkaz:
https://doaj.org/article/95cef2f6e47f464084ba9d6af5f5931a
Publikováno v:
Pharmacogenomics
Aim: Molecular alterations in drug targets may result in differential drug activity. Therefore, the authors aimed to characterize how molecular alterations in drug targets were assessed during drug development. Materials & methods: The authors analyz
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::c60e9f3f834619c14af67fd88f09952d
https://pubmed.ncbi.nlm.nih.gov/35440173
https://pubmed.ncbi.nlm.nih.gov/35440173
Autor:
Timil H. Patel, Leigh Marcus, M. Naomi Horiba, Martha Donoghue, Somak Chatterjee, Pallavi S. Mishra-Kalyani, Robert N. Schuck, Yangbing Li, Xinyuan Zhang, Jeanne Fourie Zirkelbach, Rosane Charlab, Jiang Liu, Yuching Yang, Steven J. Lemery, Richard Pazdur, Marc R. Theoret, Lola A. Fashoyin-Aje
Publikováno v:
Clinical cancer research : an official journal of the American Association for Cancer Research.
On April 17, 2020, the FDA granted accelerated approval to pemigatinib (PEMAZYRE, Incyte Corporation) for the treatment of adults with previously treated, unresectable locally advanced or metastatic cholangiocarcinoma with an FGFR2 fusion or other re
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::17ff235b94f6482a85e550b76940ca39
https://pubmed.ncbi.nlm.nih.gov/36206041
https://pubmed.ncbi.nlm.nih.gov/36206041
Autor:
Weibin Zha, Matthew L. Edin, Kimberly C. Vendrov, Robert N. Schuck, Fred B. Lih, Jawahar Lal Jat, J. Alyce Bradbury, Laura M. DeGraff, Kunjie Hua, Kenneth B. Tomer, John R. Falck, Darryl C. Zeldin, Craig R. Lee
Publikováno v:
Journal of Lipid Research, Vol 55, Iss 10, Pp 2124-2136 (2014)
Adipogenesis plays a critical role in the initiation and progression of obesity. Although cytochrome P450 (CYP)-derived epoxyeicosatrienoic acids (EETs) have emerged as a potential therapeutic target for cardiometabolic disease, the functional contri
Externí odkaz:
https://doaj.org/article/b28891d15da546688f2635126a06d9ed
Autor:
Robert N. Schuck, Michael Pacanowski
Publikováno v:
Clinical Pharmacology & Therapeutics. 111:1202-1204
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::5fd98d81e9777285f336e908ee98fd25
https://doi.org/10.1002/cpt.2347
https://doi.org/10.1002/cpt.2347
Autor:
Darrell R. Abernethy, Balaji Agoram, John M. Allen, Mark E. Arnold, Arthur J. Atkinson, Thomas J. Bateman, Kimberly Bergman, Brian Booth, David W. Boulton, Robert A. Branch, Gilbert J. Burckart, Mary Buschmann, Owen Carmichael, Christine Chamberlain, Ligong Chen, Charles E. Daniels, Promi Das, Jana G. Delfino, John N. Van Den Anker, Albert W. Dreisbach, Michael Dyszel, Justin C. Earp, M. Khair ElZarrad, Osatohanmwen J. Enogieru, Elimika Pfuma Fletcher, David M. Foster, Marilynn C. Frederiksen, Aleksandra Galetin, Pamela D. Garzone, Kathleen M. Giacomini, Megan A. Gibbs, Jack A Gilbert, Danijela Gnjidic, Charles T. Gombar, Denis M. Grant, Charles Grudzinskas, Bengt Hamren, Nicholas H.G. Holford, Shiew-Mei Huang, Renee Iacona, Nina Isoherranen, Denise Jin, Bridgette L. Jones, Gregory L. Kearns, Cindy Kortepeter, Elizabeth Kunkoski, S.W. Johnny Lau, Christopher Leptak, Juan J.L. Lertora, Lawrence J. Lesko, Jiang Liu, Qi Liu, Rajanikanth Madabushi, Raymond Miller, Diane R. Mould, Monica Muñoz, Thomas D. Nolin, Robert Joseph Noveck, R. Scott Obach, Michael Pacanowski, Mary F. Paine, Carl C. Peck, Anuradha Ramamoorthy, A. David Rodrigues, Malcolm Rowland, Chandrahas G. Sahajwalla, Martina Dagmar Sahre, Robert N. Schuck, Khushboo Sharma, Tristan Sissung, Catherine S. Stika, Chris H. Takimoto, Helen Tomkinson, Jack Uetrecht, Paolo Vicini, Karen D. Vo, John A. Wagner, Yaning Wang, Yow-Ming C. Wang, Peter G. Wells, Michael J. Wick, Sook Wah Yee, Ophelia Yin, Nathalie K. Zgheib, Lei Zhang, Hao Zhu
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_________::848d2065918d75dffbea67f6015e7476
https://doi.org/10.1016/b978-0-12-819869-8.09990-0
https://doi.org/10.1016/b978-0-12-819869-8.09990-0
Biomarkers play important roles in the practice of medicine and all phases of drug development by providing information on patient status in the clinical setting and critical information on pharmacodynamic activity, efficacy, and safety throughout dr
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_________::bdd653f40914644daf214da8fb8f2a19
https://doi.org/10.1016/b978-0-12-819869-8.00029-x
https://doi.org/10.1016/b978-0-12-819869-8.00029-x
Autor:
Robert N. Schuck, Michael Pacanowski, Jennifer L. Wilson, Issam Zineh, Oluseyi Adeniyi, Anuradha Ramamoorthy, Jielin Sun
Publikováno v:
Clinical Pharmacology & Therapeutics. 106:841-846
Clinical trial designs targeting patient subgroups with certain genetic characteristics may enhance the efficiency of developing drugs for cardiovascular disease (CVD). To evaluate the extent to which genetic knowledge translates to the CVD pipeline,
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::db23f75c4da0eb48475bfadefd9161b9
https://doi.org/10.1002/cpt.1473
https://doi.org/10.1002/cpt.1473